GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lucid Diagnostics Inc (NAS:LUCD) » Definitions » Price-to-Free-Cash-Flow

LUCD (Lucid Diagnostics) Price-to-Free-Cash-Flow : N/A (As of May. 12, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Lucid Diagnostics Price-to-Free-Cash-Flow?

As of today (2025-05-12), Lucid Diagnostics's share price is $1.13. Lucid Diagnostics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.90. Hence, Lucid Diagnostics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Lucid Diagnostics's Price-to-Free-Cash-Flow or its related term are showing as below:

LUCD's Price-to-Free-Cash-Flow is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 28.26
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Lucid Diagnostics's Free Cash Flow per Share for the three months ended in Dec. 2024 was $-0.17. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.90.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 3.80% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -66.90% per year.

During the past 6 years, Lucid Diagnostics's highest 3-Year average Free Cash Flow per Share Growth Rate was 3.80% per year. The lowest was -136.40% per year. And the median was -73.30% per year.


Lucid Diagnostics Price-to-Free-Cash-Flow Historical Data

The historical data trend for Lucid Diagnostics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lucid Diagnostics Price-to-Free-Cash-Flow Chart

Lucid Diagnostics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial - - - - -

Lucid Diagnostics Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lucid Diagnostics's Price-to-Free-Cash-Flow

For the Medical Devices subindustry, Lucid Diagnostics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lucid Diagnostics's Price-to-Free-Cash-Flow Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lucid Diagnostics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Lucid Diagnostics's Price-to-Free-Cash-Flow falls into.


;
;

Lucid Diagnostics Price-to-Free-Cash-Flow Calculation

Lucid Diagnostics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=1.13/-0.901
=N/A

Lucid Diagnostics's Share Price of today is $1.13.
Lucid Diagnostics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.90.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Lucid Diagnostics  (NAS:LUCD) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Lucid Diagnostics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Lucid Diagnostics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Lucid Diagnostics Business Description

Traded in Other Exchanges
N/A
Address
360 Madison Avenue, 25th Floor, New York, NY, USA, 10017
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Executives
Stanley Lapidus director 101 HARTWELL AVE., LEXINGTON MA 02421
Debra White director C/O PAVMED INC., ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Michael Adam Gordon officer: General Counsel ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Shaun O'neil officer: Chief Operating Officer ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Pavmed Inc. 10 percent owner 360 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10017
Lishan Aklog director, officer: Chief Executive Officer 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171
Dennis M Mcgrath officer: Chief Financial Officer C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Ronald M Sparks director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
James L Cox director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Aster Angagaw director 150 PEABODY PLACE, MEMPHIS TN 38103
Jacque J Sokolov director
David F Wurtman officer: Chief Medical Officer ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165